Dr. Pedro R. Moreno performs over one thousand cardiac coronary invasive procedures annually (including diagnostic catheterizations, angioplasties and coronary stents) with >99% success rate and <1% major complications. Trained at Harvard Medical School (Massachusetts General Hospital and Brigham and Women's Hospital), Dr. Moreno is triple board certified in Internal Medicine, Cardiology, and Interventional Cardiology.
As a world-renowned expert in atherosclerosis, Dr. Moreno has been a pioneer in the understanding of inflammation and acute coronary syndromes. Dr. Moreno described for the first time the role of macrophages in living patients with unstable angina and acute myocardial infarction in 1993. Its impact in the scientific community was evident by the immediate recognition, which opened new routes of investigation around the world. Dr. Moreno identified a significant correlation between macrophages and tissue factor, a membrane-bound protein responsible for the activation of coagulation in vivo. Consequently, his studies showed the double sword of inflammation in human atherosclerosis; i.e. plaque rupture and coronary thrombosis.
Dr. Moreno also contributed to vascular biologic aspects of restenosis, a renarrowing process that occurs in coronary or peripheral arteries after stenting. His work established the link between inflammation and smooth muscle cell proliferation in-vivo. These findings provided the rationale for revolutionary state of the art therapies including anti-inflammatory and anti-proliferative drug-eluting stents, currently used in daily practice around the world. In addition, Dr. Moreno integrated his observations in a major health problem in America: diabetes mellitus. His comprehensive approach to the disease in patients with diabetes lead to a major breakthrough in cardiovascular medicine: The importance of neovascular microangiopathy in the diabetic atherosclerotic plaque. Dr. Moreno is now investigating these plaque microvessels leading to dramatic increases in heart attacks in the diabetic population.
Dr. Moreno has additional extensive experimental research in novel diagnostic and therapeutic modalities for vulnerable plaques, the most common cause of a heart attack. His work using near-infrared spectroscopy is now acknowledged as a major advance in the elusive field of percutaneous coronary plaque characterization. Furthermore, Dr. Moreno developed atherosclerotic modes of vulnerable plaques involving swine and hypercholesterolemic rabbits, allowing for testing novel therapies as potential adjunctive treatment for vulnerable plaques.
Dr. Moreno serves as an advisory to several government agencies including the FBI in the US and the National Cardiovascular Center in Spain. He has several recognitions including the Young Investigator Award followed by the Senior Investigator Award from The Vulnerable Plaque Organization. Dr. Moreno also received the excellence award from the Colombian Society of Cardiology. Dr. Moreno is an official reviewer for the American Heart Association and several scientific journals including Annals of Internal Medicine, Circulation, and The Journal of the American College of Cardiology, American Journal of Cardiology, American Heart Journal, and European Heart Journal. He is honorary member of several international cardiology organizations including the Chilean Society of Cardiology, the Venezuelan Society of Cardiology, the Colombian Society of Cardiology and the Dominican Republic Society of Cardiology. Finally, is an excellent teacher and a mentor of clinical and research fellows at the Mount Sinai Hospital in New York City.
In The News: Dr. Pedro Moreno discusses cardiac catheterization in The Daily News feature The Daily Check-Up
MD, Universidad Javeriana
Residency, Internal Medicine
Residency, Internal Medicine
Brigham and Women's Hospital, Harvard Medical School
Fellowship, Interventional Cardiology
Massachusetts General Hospital
Appointed Reviewer for PCR Annual Scientific Sessions
Levy AP, Purushothaman KR, Guetta J, Ashleh R, Moreno PR, Cohen O, Zias EA, Benhayon D, Fuster V, Marsh S. Decreased D163 expression in individuals with the Hp2-2 genotype and diabetes: Implications for plaque vulnerability. Circ Res 2007; 101: 106-110.
Levy AP, Levy JE, Kalet-Litman , Miller-Lotan R, Levy NS, Moreno PR, Guetta J, Yang C, Purushothaman KR, Fuster V, Asaf R. Haptoglobin genotype is a determinant of iron, lipid peroxidation and macrophage accumulation in the atherosclerotic plaque. Arteriosclerosis Thromb Vasc Biol 2007; 27(1): 134-140.
Sanz J, Fuster V, Moreno PR. The year in atherothrombosis. J Am Coll Cardiol 2007; 49(16): 1740-1749.
Fuster V, Moreno PR. New Aspects in the Pathogenesis of Diabetic Atherothrombosis. JACC 2004; 44: 2293-2300.
Fuster V, Moreno PR. The Year in Atherothrombosis. JACC 2004; 44: 2099-2110.
Moreno PR, Purushothaman KR, O'Connor WN, Echeverri D, Truszczynska H, Fuster V. Tunica media and plaque neovascularization is increased in ruptured atherosclerotic lesions of the human aorta: implications for plaque vulnerability. Circulation 2004 Oct 5; 110(14): 2032-2038.
Moreno PR, Purushothaman KR, Fuster V, Sanz J, Zias E. Neovascularization in Human Atherosclerosis. Curr Mol Med 2006; 6: 457-477.
Moreno PR, Fuster V, Sanz J. Special Issue on Atherosclerosis [editorial]. Curr Mol Med 2006; 6: 437-438.
Fuster V, Moreno PR. The Year in Atherothrombosis. Letter response. JACC 2006; 47: 689.
Moreno PR, Purushothaman KR, Fuster V, Levy AP, Sirol M. Neovascularization in Human Atherosclerosis. Circulation 2006; 113: 2245-2252.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Moreno during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.